Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Receivables - Net: 2020-2024

Historic Receivables - Net for Whitehawk Therapeutics (WHWK) over the last 4 years, with Dec 2024 value amounting to $5.9 million.

  • Whitehawk Therapeutics' Receivables - Net rose 7.56% to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.9 million, marking a year-over-year increase of 7.56%. This contributed to the annual value of $5.9 million for FY2024, which is 7.56% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Receivables - Net stood at $5.9 million for FY2024, which was up 7.56% from $5.5 million recorded in FY2023.
  • Whitehawk Therapeutics' Receivables - Net's 5-year high stood at $14.1 million during FY2020, with a 5-year trough of $1.9 million in FY2022.
  • Moreover, its 3-year median value for Receivables - Net was $5.5 million (2023), whereas its average is $4.4 million.
  • Data for Whitehawk Therapeutics' Receivables - Net shows a peak YoY skyrocketed of 194.74% (in 2023) over the last 5 years.
  • Over the past 4 years, Whitehawk Therapeutics' Receivables - Net (Yearly) stood at $14.1 million in 2020, then reached $1.9 million in 2022, then skyrocketed by 194.74% to $5.5 million in 2023, then grew by 7.56% to $5.9 million in 2024.